DRMA Leads Health Care Gainers
Dermata Therapeutics stock rises 44.4% to $1.56 after Q2 earnings report
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.
Dermata Therapeutics stock rises 44.4% to $1.56 after Q2 earnings report
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.